YAP1 and colorectal carcinoma: Further preclinical studies and clinical studies are needed to explore the potentials of abemaciclib in managing CRC, particularly given that abemaciclib reduces YAP1 protein levels more significantly than trilaciclib and palbociclib (Figure 1B).